Toll样受体和前列腺癌
Toll样受体和前列腺癌
摘要
Toll样受体（Tolllikereceptors，TLRs）是进化中比较保守的一个受体家族，至少包括10个成员；TLRs属模式识别受体（patternrecognitionreceptor，PRR），不仅在激活天然免疫中发挥重要的作用，而且还调节获得性免疫，是连接天然免疫和获得性免疫的桥梁。近来发现，部分TLRs基因序列的多态性与前列腺癌的发生存在相关性；TLRs介导的信号通路能够活化树突状细胞，继而直接增强宿主对肿瘤天然免疫及获得性免疫应答的能力。我们围绕TLRs与前列腺癌的研究进展进行综述。
出处
《中国肿瘤临床与康复》
2009年第6期568-570,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
参考文献13
-
1Andreani V, Gatti G, Simonella L, et al. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo[J]. Cancer Res, 2007 ,67(21) :10519-15027.
-
2Wagenlehner FM, Elkahwaji JE, Algaba F, et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma [J]. BJU Int, 2007, 100(4) :733-737.
-
3Cheng I, Plummer SJ, Casey G, et al. Toll-like receptor 4 genetic variation and advanced prostate cancer risk [ J ]. Cancer Epidemiol Biomarkers Prey, 2007, 16(2) :352-355.
-
4Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study [ J ]. Cancer Res, 2004, 64(8) :2918-2922.
-
5Chen YC, Giovannucci E, Lazarus R, et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer [ J ]. Cancer Res,2005,65 (24) : 11771-11778.
-
6Sun J, Wiklund F, Zheng SL, et al. Sequence variants in Toll- like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk[J]. J Natl Cancer Inst, 2005, 97(7) :525-532.
-
7Sun J, Turner A, Xu J, et al. Genetic variability in inflammation pathways and prostate cancer risk [ J ]. Urol Oncol, 2007, 25 (3) :250-259.
-
8Sun J, Wiklund F, Hsu FC, et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk [J]. Cancer Epidemiol Biomarkers Prey, 2006, 15 ( 3 ) :480-485.
-
9Chen YC, Giovannucci E, Kraft P, et al. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer [ J ]. Cancer Epidemiol Biomarkers Prey, 2007, 16(10) : 1982-1989.
-
10Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro[J]. Prostate, 2007, 67(7) :774-781.
-
1闫新星,王晶,克晓燕.Toll样受体与血液恶性肿瘤[J].肿瘤研究与临床,2015,27(11):788-790. 被引量：1
-
2肖朝朝,吴发明.Toll样受体在结肠癌发生发展中作用的研究进展[J].广东医学,2014,35(24):3924-3926.
-
3胡婷,刘加军.Toll样受体及其与恶性血液病关系的研究进展[J].新医学,2008,39(12):827-828.
-
4高小姣,陈莉.TLR3对细胞凋亡相关信号通路的调控[J].基础医学与临床,2014,34(10):1430-1433.
-
5杨洁,范华骅,章平,高峰.NKT细胞在抗肿瘤免疫中的作用及其机制[J].生命科学,2006,18(1):62-66. 被引量：5
-
6顾炎,曹雪涛.模式识别受体与肿瘤微环境研究进展[J].中国肿瘤生物治疗杂志,2015,22(2):143-150. 被引量：3
-
7杜宇琛,林苹.肿瘤树突状细胞疫苗治疗的临床研究进展[J].四川肿瘤防治,2003,16(1):49-52.
-
8刘营营,王宇,韩桂萍.Toll样受体4与炎性肠病和结肠癌[J].肿瘤学杂志,2013,19(9):735-738. 被引量：1
-
9高春玲,王笑良,吴晓安,叶性景,程小峰,陈建清.吉西他滨/长春瑞滨对Ⅲ～Ⅳ期非小细胞肺癌的放射增敏作用[J].实用癌症杂志,2012,27(1):48-51. 被引量：7
-
10姜娜,辛文妤,陆丽娜,Baud V,Karin M.核因子-κB是癌症治疗的好靶点吗?希望和缺陷[J].国际药学研究杂志,2009,36(4):300-303. 被引量：10
